

# ANRS C013 HEPAVIH - Inter-cohort and clinical centers collaboration of subjects co-infected by human immunodeficiency virus and hepatitis C

Head :Wittkop Linda, INSERM, U1219, Centre de Recherche Inserm Bordeaux Publique Health, équipe Morpheus, CMG-EC  
Salmon Dominique, Services des Maladies Infectieuses et Tropicales  
Sogni Philippe, Service d'Hépatologie

Last update : 08/07/2019 | Version : 3 | ID : 3626

## General

### Identification

Detailed name Inter-cohort and clinical centers collaboration of subjects co-infected by human immunodeficiency virus and hepatitis C

Sign or acronym ANRS C013 HEPAVIH

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation ClinicalTrials : NCT03324633 ; CPP : CG/LG/CC 2005-466

### General Aspects

Medical area Immunology  
Infectious diseases

Health determinants Lifestyle and behavior

Keywords Adults, disease carriers, cured, treatment, co-infection

### Scientific investigator(s) (Contact)

Name of the director Wittkop

Surname Linda

Address VIH, Hépatites Virales et comorbidités :  
épidémiologie clinique et santé publique /  
Multimorbidity and Public Health in Patients with HIV  
or Hepatitis (MORPH3Eus)  
CMG-EC de l'INSERM U1219 / ANRS  
Université de Bordeaux  
ISPED  
146, rue Léo Saignat ? CS61292

33076 Bordeaux cedex  
FRANCE

Phone +33 (0)5 57 57 13 92  
Email linda.wittkop@u-bordeaux.fr  
Unit INSERM, U1219, Centre de Recherche Inserm  
Bordeaux Publique Health, équipe Morpheus, CMG-  
EC  
Organization Inserm

Name of the director Salmon  
Surname Dominique  
Phone +33 (0) 1 42 34 79 56  
Email dominique.salmon@aphp.fr  
Unit Services des Maladies Infectieuses et Tropicales  
Organization Assistance Publique des Hôpitaux de Paris -  
Hôpitaux Paris Centre, Université Paris Descartes

Name of the director Sogni  
Surname Philippe  
Address Hôpital Cochin  
Email philippe.sogni@aphp.fr  
Unit Service d'Hépatologie  
Organization Assistance Publique des Hôpitaux de Paris -  
Hôpitaux Paris Centre, Université Paris Descarte,  
Inserm

## Collaborations

Participation in projects,  
networks and consortia Yes

## Funding

Funding status Mixed

Details ANRS, INSERM, Laboratoires Glaxo-SmithKline,  
Roche, Schering Plough et Janssen

## Governance of the database

Sponsor(s) or organisation(s) responsible ANRS - AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES

Organisation status Public

Presence of scientific or steering committees Yes

## Additional contact

Name of the contact Esterle

Surname Laure

Address VIH, Hépatites Virales et comorbidités :  
épidémiologie clinique et santé publique /  
Multimorbidity and Public Health in Patients with HIV  
or Hepatitis (MORPH3Eus)  
CMG-EC de l'INSERM U1219 / ANRS  
Université de Bordeaux  
ISPED  
146, rue Léo Saignat ? CS61292  
33076 Bordeaux cedex  
FRANCE

Phone +(33)5 57 57 92 71

Email laure.esterle@u-bordeaux.fr

Unit INSERM, U1219, Centre de Recherche Inserm  
Bordeaux Public Health, équipe Morpheus, CMG-  
EC

Organization Inserm

Name of the contact ANRS

Address 101 rue de Tolbiac 75013 Paris

Unit Service de recherches fondamentales, cliniques et  
thérapeutiques sur les Hépatites virales

Organization ANRS

## Main features

### Type of database

Type of database Study databases

Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Dates and inclusions duration: Phase 1: 2005-2008 (3 years) Phase 2: 2011-2014 (3 years)

## Database objective

Main objective	<p>Short term:</p> <ul style="list-style-type: none"> <li>- Describe patient's characteristics</li> <li>- Analyze factors associated to a treatment of hepatitis C: beginning of the treatment, continuation or stop of the treatment.</li> <li>- Validate the field performance of not-invasive markers of hepatic fibrosis.</li> </ul> <p>Mid-term:</p> <ul style="list-style-type: none"> <li>- Realize an observational study of the evolution of hepatitis during an anti-VHC treatment, in an antiviral situation</li> <li>- Study the clinical and biological tolerance to the different treatments.</li> <li>- Study the impact of the observance of the treatment anti HIV and the life quality of patients.</li> </ul> <p>Long term:</p> <p>Study the natural history of chronic hepatitis, in particular at the stage of cirrhosis.</p> <ul style="list-style-type: none"> <li>- Analyze the factors associated to the evolution to fibrosis, to a decompensated hepatic disease or an hepatocellular carcinoma.</li> <li>- Evaluate the effects of antiretroviral agents on the evolution of not-treated hepatitis</li> <li>- Study the potential interactions between different virus of hepatitis</li> </ul>
----------------	--

Inclusion criteria	Adults infected by HIV virus carriers of VHC or cured after anti-VHC treatment, or spontaneously healed without anti-VHC treatment or benefiting from an anti-VHC tritherapies.
--------------------	---

## Population type

Age	<p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p>
-----	---

Population covered	Sick population
Pathology	B24 - Unspecified human immunodeficiency virus [HIV] disease
	B15-B19 - Viral hepatitis
Gender	Male Woman Other
Geography area	National
Detail of the geography area	French multi-centers cohort (28 centers)
<b>Data collection</b>	
<b>Dates</b>	
Date of first collection (YYYY or MM/YYYY)	01/2006
Date of last collection (YYYY or MM/YYYY)	09/2022
<b>Size of the database</b>	
Size of the database (number of individuals)	[1000-10 000[ individuals
Details of the number of individuals	1849 in june 2018
<b>Data</b>	
Database activity	Current data collection
Type of data collected	Clinical data Declarative data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Details of collected clinical data	Clinical examination at inclusion and during the follow-up. Information collected during the clinical examination: weigh, height, waist and hips circumference
Declarative data (detail)	Paper self-questionnaire Face to face interview

Details of collected declarative data	Clinical examination at inclusion and during the follow-up. Information collected during the clinical examination: weigh, height, waist and hips circumference
Paraclinical data (detail)	Radiology, evaluation of the hepatic fibrosis
Biological data (detail)	Blood check
Presence of a biobank	Yes
Contents of biobank	Whole blood Serum Plasma
Details of biobank content	Serum bank, plasma bank, DNA bank, total blood, tissues bank in a non-systematic way
Health parameters studied	Health care consumption and services Quality of life/health perception
Care consumption (detail)	Medical/paramedical consultation Medicines consumption
<b>Procedures</b>	
Data collection method	Self-questionnaire: filled from a paper questionnaire. Interviews: filled from a paper questionnaire .Clinical examination: manual data entry .Biological examination: manual data entry
Classifications used	---
Quality procedure(s) used	Data utilization possible for academic teams and for industrials. Temporary access condition : project accepted by the scientific committee
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Details on monitoring of participants	Annual or bi-annual, specific according to the anti-VHC treatment
Links to administrative sources	No
<b>Promotion and access</b>	
<b>Promotion</b>	
Link to the document	<a href="#">Liste publications COHORTE ANRS CO13 HEPAVIH 20180830.pdf</a>

Description List of publications in HAL

Link to the document <http://www.ncbi.nlm.nih.gov/pubmed/?term=HEPAVIH+OR+ANRS+CO13+OR+%28coherence+AND+%28hiv+OR+AIDS%29%29>

Description List of publications in Pubmed

## Access

Presence of document that lists variables and coding procedures Yes

Terms of data access (charter for data provision, format of data, availability delay) Data utilization possible for academic teams and for industrials. Temporary access condition : project accepted by the scientific committee

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only